Nuvalent CFO Sells Over $1.2 Million in Shares

Alexandra Balcom reduces her position by 11.79% through multiple transactions

Apr. 4, 2026 at 10:05am

Got story updates? Submit your updates here. ›

Nuvalent, Inc. (NASDAQ:NUVL) Chief Financial Officer Alexandra Balcom sold 11,430 shares of the company's stock on April 1st at an average price of $105.21, totaling $1,202,550.30. This transaction reduced Balcom's position by 11.79% to 85,533 shares, worth approximately $8.999 million. Balcom also made two previous share sales in January, totaling around $721,313.

Why it matters

Insider transactions, especially by C-suite executives like the CFO, can provide insight into a company's financial health and management's confidence in the business. Balcom's substantial sale, while still maintaining a sizable stake, may signal a belief that Nuvalent's stock price has reached an attractive level for partial liquidation.

The details

Balcom's April 1st sale of 11,430 shares at an average price of $105.21 resulted in total proceeds of $1,202,550.30. This transaction reduced her position by 11.79% to 85,533 shares, worth approximately $8.999 million based on Nuvalent's current stock price around $105. Earlier in January, Balcom also sold 4,236 shares for $412,247.52 and 3,181 shares for $309,065.96, totaling around $721,313 across those two transactions.

  • On April 1, 2026, Balcom sold 11,430 shares.
  • On January 6, 2026, Balcom sold 3,181 shares.
  • On January 5, 2026, Balcom sold 4,236 shares.

The players

Alexandra Balcom

The Chief Financial Officer of Nuvalent, Inc.

Nuvalent, Inc.

A clinical-stage precision oncology company focused on developing targeted therapies for patients with genetically defined cancers.

Got photos? Submit your photos here. ›

What’s next

Investors will likely continue to monitor Nuvalent's stock performance and any further insider trading activity, as Balcom's substantial sale could signal a potential shift in the company's outlook or management's confidence.

The takeaway

Balcom's sale of over $1.2 million in Nuvalent shares, while still maintaining a sizable stake, may indicate that the company's stock price has reached an attractive level for partial liquidation by a key executive. This transaction provides insight into management's perspective on the company's financial health and future prospects.